Cargando…

Advancing clinical trial design in pulmonary hypertension

In pulmonary hypertension, as in many other diseases, there is a need for a smarter approach to evaluating new treatments. The traditional randomized controlled trial has served medical science well, but constrains the development of treatments for rare diseases. A workshop was established to consid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grieve, Andy P., Chow, Shien-Chung, Curram, John, Dawe, Stephen, Harnisch, Lutz O., Henig, Noreen R., Hung, Hsien Ming J., Ivy, D. Dunbar, Kawut, Steven M., Rahbar, Mohammad H., Xiao, Shen, Wilkins, Martin R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications 2013
Materias:	Pulmonary Hypertension–Academic Research Consortium: Novel Clinical Trial Designs
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641733/ https://www.ncbi.nlm.nih.gov/pubmed/23662200 http://dx.doi.org/10.4103/2045-8932.109933

Ejemplares similares

The pulmonary hypertension academic research consortium
por: Rich, Stuart
Publicado: (2013)

Clinical trials in neonates and children: Report of the pulmonary hypertension academic research consortium pediatric advisory committee
por: Adatia, Ian, et al.
Publicado: (2013)

Clinical trials in pulmonary hypertension: Time for a consortium
por: Newman, John H., et al.
Publicado: (2013)

Identifying Patients with Group 3 Pulmonary Hypertension Associated with COPD or ILD Using an Administrative Claims Database
por: Heresi, Gustavo A., et al.
Publicado: (2022)

Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH
por: Gall, Henning, et al.
Publicado: (2018)

Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular–Pulmonary Arterial Coupling
por: Taran, Irina N., et al.
Publicado: (2018)

The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension
por: Wronski, Samantha L., et al.
Publicado: (2019)

Pulmonary Hypertension in Heart Failure Patients
por: Rao, Sriram D, et al.
Publicado: (2020)

Can a New Scoring System Improve Prediction of Pulmonary Hypertension in Newly Recognised Interstitial Lung Diseases?
por: Sobiecka, Małgorzata, et al.
Publicado: (2020)

Updating clinical endpoint definitions
por: Hassoun, Paul M., et al.
Publicado: (2013)

The Early Growth Genetics (EGG) and EArly Genetics and Lifecourse Epidemiology (EAGLE) consortia: design, results and future prospects
por: Middeldorp, Christel M., et al.
Publicado: (2019)

Ultra-low-dose quadruple combination blood pressure–lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol
por: Chow, Clara K., et al.
Publicado: (2021)

Effect of A Reduction in glomerular filtration rate after NEphrectomy on arterial STiffness and central hemodynamics: Rationale and design of the EARNEST study()
por: Moody, William E., et al.
Publicado: (2014)

Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200–499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study
por: Budoff, Matthew, et al.
Publicado: (2018)

Wake Forest University long‐term follow‐up of type 2 myocardial infarction: The Wake‐Up T2MI Registry
por: Jogu, Hanumantha R., et al.
Publicado: (2019)

Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension
por: Morrell, Nicholas W., et al.
Publicado: (2013)

Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular‐only pacing
por: Filippatos, Gerasimos, et al.
Publicado: (2017)

Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study
por: Bhatt, Deepak L., et al.
Publicado: (2019)

Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo‐controlled, non‐inferiority ARIES HM3 trial
por: Mehra, Mandeep R., et al.
Publicado: (2021)

Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study
por: Capell, Warren H., et al.
Publicado: (2021)

Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial
por: Hess, Connie N., et al.
Publicado: (2022)

Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design
por: Böhm, Michael, et al.
Publicado: (2020)

Rationale and design of a smartphone‐enabled, home‐based exercise program in patients with symptomatic peripheral arterial disease: The smart step randomized trial
por: Harzand, Arash, et al.
Publicado: (2020)

Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study
por: Teerlink, John R., et al.
Publicado: (2017)

Implementation of Multifaceted Patient-Centered Treatment Strategies for Intensive Blood Pressure Control (IMPACTS): Rationale and design of a cluster-randomized trial()()
por: Mills, Katherine T., et al.
Publicado: (2020)

Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)
por: Ambrosy, Andrew P., et al.
Publicado: (2021)

Radiosurgery for ventricular tachycardia: preclinical and clinical evidence and study design for a German multi-center multi-platform feasibility trial (RAVENTA)
por: Blanck, Oliver, et al.
Publicado: (2020)

Rationale and design of a navigator‐driven remote optimization of guideline‐directed medical therapy in patients with heart failure with reduced ejection fraction
por: Blood, Alexander J., et al.
Publicado: (2019)

Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)–Coalition IV trial()()
por: Lopes, Renato D., et al.
Publicado: (2021)

Mineralocorticoid Receptor Antagonist Pretreatment to MINIMISE Reperfusion Injury After ST‐Elevation Myocardial Infarction (The MINIMISE STEMI Trial): Rationale and Study Design
por: Bulluck, Heerajnarain, et al.
Publicado: (2015)

Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial
por: Morrow, Andrew J, et al.
Publicado: (2020)

Design and Rationale of the PRAGUE‐12 Trial: A Large, Prospective, Randomized, Multicenter Trial That Compares Cardiac Surgery With Left Atrial Surgical Ablation With Cardiac Surgery Without Ablation in Patients With Coronary and/or Valvular Heart Disease Plus Atrial Fibrillation
por: Straka, Zbyněk, et al.
Publicado: (2012)

Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial()
por: Berry, Colin, et al.
Publicado: (2013)

Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration
por: Pitcher, Alex, et al.
Publicado: (2015)

Rationale and design of the Clinical Evaluation of Magnetic Resonance Imaging in Coronary heart disease 2 trial (CE-MARC 2): A prospective, multicenter, randomized trial of diagnostic strategies in suspected coronary heart disease
por: Ripley, David P., et al.
Publicado: (2015)

Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERIC‐ONC Study—A Single‐Center, Blinded, Randomized Controlled Trial
por: Chung, Robin, et al.
Publicado: (2016)

Efficacy and Safety of Alirocumab as Add‐on Therapy in High–Cardiovascular‐Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies
por: Robinson, Jennifer G., et al.
Publicado: (2014)

Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy
por: Haghikia, Arash, et al.
Publicado: (2015)

Design and Rationale of the RE‐DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting
por: Cannon, Christopher P., et al.
Publicado: (2016)

Drug‐coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET‐SMALL 2
por: Gilgen, Nicole, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h14epg6iks1r7646r5ua1tl7aj